Join the Wegovy group to help and get support from people like you.
Wegovy News (Page 4)
No Suicide Risk Associated With GLP-1 Drugs
FRIDAY, Feb. 28, 2025 – GLP-1 drugs like Ozempic/Wegovy don’t increase a person’s risk of suicidal actions or thoughts, a new study has concluded. Earlier research had potentially linked these drugs ...
Depression Risk Lower With GLP-1 Receptor Agonists Versus DPP-4 Inhibitors in Seniors
MONDAY, Feb. 24, 2025 – For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared...
Ozempic, Wegovy Linked To Potential Vision Loss
MONDAY, Feb. 24, 2025 – People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye condition that affects the optic nerve, a new study says....
Weight-Loss Drugs Could Help Extend Life of Replacement Joints
MONDAY, Feb. 24, 2025 (HealthDay news) – Even slight weight loss spurred on by cutting-edge GLP-1 drugs can help prevent replacement knees and hips from wearing out, a new study suggests. People...
Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations
FRIDAY, Feb. 21, 2025 – For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1...
Senators Call on FDA to Act Against Misleading Weight-Loss Drug Commercials
WEDNESDAY, Feb. 12, 2025 – Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of prescription of injectable...
GLP-1 Meds Can Work Wonders for Kidney Health
TUESDAY, Feb. 11, 2025 – Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new research shows....
Can GLP-1 Meds Harm Your Eyes?
MONDAY, Feb. 10, 2025 – Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye trouble, according...
New Facial Plastic Surgery Survey Illustrates Impact of GLP-1 Receptor Agonists
FRIDAY, Feb. 7, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of facial plastic surgery, according to the results of...
Prescriptions for Obesity Management Drugs Increasing
THURSDAY, Feb. 6, 2025 – Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online search trends, according to a study published online...
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 – Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found that a drug in the same class called exenatide,...
Weight Loss Boosts Long-Term Health of Kids With Obesity
TUESDAY, Jan. 28, 2025 – Helping kids with obesity drop pounds can have a huge impact on their future health. When these children and teens lose weight, they are less likely to have type 2 diabetes,...
Several Factors Play Role in Semaglutide Initiation for Obesity Without Diabetes
THURSDAY, Jan. 23, 2025 – Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes, according to a study published...
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
TUESDAY, Jan. 21, 2025 – Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and...
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
WEDNESDAY, Jan. 22, 2025 – Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published ...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction